Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Innate Pharma (IPHA)

NASDAQ
Currency in USD
1.450
-0.060(-3.97%)
Closed
After Hours
1.570+0.120(+8.276%)
IPHA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
1.4101.510
52 wk Range
1.2903.150
Key Statistics
Edit
Prev. Close
1.45
Open
1.51
Day's Range
1.41-1.51
52 wk Range
1.29-3.15
Volume
14.9K
Average Vol. (3m)
10.38K
1-Year Change
-44.44%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPHA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.253
Upside
+348.529%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Innate Pharma Company Profile

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Employees
191
Market
France

Compare IPHA to Peers and Sector

Metrics to compare
IPHA
Peers
Sector
Relationship
P/E Ratio
−3.4x−2.4x−0.7x
PEG Ratio
−0.07−0.120.00
Price / Book
4.0x1.4x2.6x
Price / LTM Sales
3.4x4.4x3.2x
Upside (Analyst Target)
-202.5%45.9%
Fair Value Upside
Unlock3.8%7.6%Unlock

Analysts' Recommendations

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.412

(+411.17% Upside)

People Also Watch

1.33
AVQ
+1.99%
3.61
MDM
+1.12%
44.20
NRO
-0.23%
6.93
ADOC
-5.71%
0.79
ABS
0.00%

FAQ

What Is the Innate Pharma (IPHA) Stock Price Today?

The Innate Pharma stock price today is 1.45

What Stock Exchange Does Innate Pharma Trade On?

Innate Pharma is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Innate Pharma?

The stock symbol for Innate Pharma is "IPHA."

What Is the Innate Pharma Market Cap?

As of today, Innate Pharma market cap is 118.79M.

What is Innate Pharma Earnings Per Share?

The Innate Pharma EPS is -0.422.

From a Technical Analysis Perspective, Is IPHA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.